Concourse Financial Group Securities, Inc. Salarius Pharmaceuticals, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.52 Billion
  • Q1 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 15, 2022
BUY
$0.17 - $0.25 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$0.16 - $0.42 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$0.34 - $0.54 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$0.49 - $1.01 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$0.8 - $1.15 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$1.02 - $1.52 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$1.0 - $3.0 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$0.65 - $1.34 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
BUY
$0.77 - $1.52 $0 - $0
0 New
0 $0
Q2 2020

Aug 13, 2020
BUY
$0.6 - $1.82 $0 - $0
0 New
0 $0
Q1 2020

May 13, 2020
BUY
$0.56 - $3.82 $0 - $0
0 New
0 $0
Q4 2019

Feb 14, 2020
BUY
$3.02 - $5.9 $0 - $0
0 New
0 $0
Q3 2019

Nov 13, 2019
BUY
$5.28 - $20.25 $0 - $0
0 New
0 $0

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $5.43M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email